Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Credit Suisse Starts Regeneron Pharma (REGN) at Neutral
January 20, 2016 6:36 AM ESTCredit Suisse initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Neutral rating and a price target of $552.00.
Analyst Alethia Young commented, "We are initiating coverage of Regeneron with a Neutral rating and a $552 target price. We are still positive on the... More
